One month after CD22 CAR-T infusion, among patients with grade 3 or higher cytopenia, recovery to grade ≤ 2 lymphopenia was observed in 82.6%, neutropenia in 80%, anemia in 40%, and thrombocytopenia in 50%. The gene discussed is CD22; the disease is anemia.